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Background: Deleted in malignant brain tumors 1 (DMBT1) is an innate defence protein expressed in the lungs of
preterm infants and adults. Recent studies showed that DMBT1 is important in angiogenesis and can bind to
different growth factors including VEGF. We aimed at examining relationships between VEGF and IL-6 levels to
DMBT1 expression in the lungs of preterm and term infants and in lung epithelial cells in vitro.
Methods: We examined by ELISA VEGF levels in 120 tracheal aspirates of 57 preterm and term infants and tested
for correlation with different perinatal factors as well as with DMBT1 levels. To examine the effect of DMBT1 on
VEGF and IL-6 expression we compared type II lung epithelial A549 cells stably transfected with a DMBT1 expression
plasmid (DMBT1+ cells) to A549 cells stably transfected with an empty expression plasmid (DMBT1- cells). The
concentrations of VEGF and IL-6 were determined via ELISA in the supernatant of the unstimulated cells and
after stimulation with LPS, TNFα and Phorbol-12-myristate-13-acetate (PMA).
Results: The VEGF levels in the tracheal aspirates of preterm and term infants were significantly correlated with
DMBT1 levels (p = 0.0032), the postnatal age (p = 0.0073) and the presence of neonatal infection/sepsis (p = 0.0002).
Unstimulated DMBT1+ A549 cells showed significantly higher VEGF expression (p = 0.0017) than DMBT1- cells. Significantly
elevated VEGF levels were also confirmed for DMBT1+ cells after stimulation with TNFα (p = 0.0008), LPS (p = 0.0232) and
PMA (p = 0.0025). The IL-6 levels were comparable in DMBT1+ versus DMBT1- cells without stimulation (p = 0.6028), but
they were significantly reduced in DMBT1+ cells after stimulation with TNFα (p = 0.0003), LPS (p = 0.0088) and
PMA (p = 0.0039).
Conclusions: The data indicate that DMBT1 promotes VEGF and suppresses IL-6 production in alveolar tissues,
which could point to DMBT1 having a possible role in the transition from inflammation to regeneration and being a
potentially useful clinical marker.
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DMBT1, a member of the scavenger receptor cysteine-
rich (SRCR) protein family, is known as a protein with
functions in innate immunity, inflammation and epithelial
cell differentiation [1-3]. Especially tissues with functions in
maintaining a barrier to the environment as, for example,
the lung or the gut show DMBT1 expression, which is up-* Correspondence: Hanna.Mueller@uk-essen.de
1Department of Pediatrics I, Neonatology, University Hospital Essen,
University Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany
2Division of Neonatology, Department of Pediatrics, University of Heidelberg,
Im Neuenheimer Feld 430, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
© 2015 Müller et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.regulated upon inflammation [4-6]. Recently, DMBT1 has
been reported to also exert functions in angiogenesis
by influencing proliferation, migration and adhesion of
endothelial cells. These functions could include binding of
DMBT1 to different growth factors such as vascular endo-
thelial growth factor (VEGF) and epidermal growth factor
(EGF) [7].
The vascular endothelial growth factor (VEGF) repre-
sents a proangiogenic growth factor produced by cells such
as pneumocytes, keratinocytes, macrophages, hepatocytes,
and smooth muscle cells [8]. In various tissues, VEGF plays
a role in normal and pathological angiogenesis, endothelialThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Correlation of non-constant parameters with the
VEGF concentration in 120 tracheal aspirates of 57
infants
Parameter p-value
Postnatal age (days) 0.0073
DMBT1 concentration in tracheal aspirates 0.0032
Infection/sepsis 0.0002
Treatment with indomethacin 0.1669
Surgery 0.8733
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sels, embryonic development, microvascular permeability,
and inflammatory processes.
VEGF is highly expressed in the lung and has multiple
functions in the pulmonary tissue: It is necessary for
lung development as well as for the structural mainten-
ance during adult life [9-11]. Furthermore, VEGF affects
the growth, proliferation and differentiation of type II
pneumocytes [12,13]. Type II pneumocytes express the
VEGF receptor VEGFR-2 [14], and VEGF up-regulates
surfactant protein B and C [13]. Several studies described a
role of VEGF in acute and chronic disease of the lung such
as acute respiratory distress syndrome (ARDS), emphysema
or pulmonary hypertension, pulmonary fibrosis, sarcoidosis,
and after lung transplantation [9,14,15]. Beyond that, VEGF
plays also a role in respiratory diseases of preterm infants,
in the alveolarization of preterm lungs with respiratory dis-
tress syndrome characterized by edema and pulmonary
inflammation, and in lungs with bronchopulmonary dyspla-
sia [8,13,16,17]. Furthermore, VEGF is important for the
pulmonary endothelial cells by functioning as a mitogen,
survival and differentiation factor, promoting angiogenesis,
and regulating the permeability of the endothelium [9].
Recent evidence that DMBT1 and VEGF are function-
ally linked in the regulation of endothelial cells and
neoangiogenesis [7] prompted us to analyze as to whether
similar relationships exist in the respiratory tract.
Methods
Patients and tracheal aspirates
To determine the VEGF concentrations we measured
120 tracheal aspirates from 57 included preterm and
term infants (27 males, 30 females) treated at the Perinatal
Center of the University of Heidelberg. These infants were
part of the patients included in earlier studies of DMBT1
levels [18,19]. The newly determined VEGF levels were
analyzed for correlation with DMBT1 levels from these
earlier studies. The study was approved by the Ethics
Committee of the University of Heidelberg, Germany, and
the parents agreed by informed consent. The mean gesta-
tional age was 27.5 ± 4.2 weeks (postmenstrual age, range:
23–40 weeks), and the mean birth weight was 1128 ± 839 g
(range: 370 – 3610 g).
The tracheal aspirates were obtained by applying 0.5-
1.0 ml 0.9% sodium chloride solution into the endotracheal
tubes and suctioning after three breaths of manual or
mechanical ventilation. To adjust for different dilution
factors associated with this procedure, we normalized the
measured concentrations of VEGF or DMBT1 to the total
protein content, which was detected with the bicinchoninic
acid (BCA) protein assay (Pierce, Rockford, IL, USA).
Different factors were tested for correlation with VEGF
levels in the tracheal aspirates, including parameters which
vary within a patients’ observational period (postnatal agein days and relative DMBT1 level in the tracheal aspirates,
treatment with indomethacin and the occurrence of neo-
natal infection/sepsis or the need of surgery at distinct
days of life; Table 1) as well as the following parameters,
which remain constant for each patient: gestational age
(postmenstrual age in weeks), birth weight, bronchopul-
monary dysplasia (yes or no; defined as additional oxygen
required at 36 weeks of corrected gestational age with
abnormal radiological findings of the lung), asphyxia
(yes or no), intraventricular hemorrhage (all grades),
cerebral hemorrhage (intraventricular, cerebellar; yes
or no), maximal grade of respiratory distress syndrome
(RDS; no RDS or grade 1–4 according to Giedion et al.
[20]), survival (yes or no), antenatal corticosteroids for
lung development (complete, yes or no), maternal infec-
tion defined by increased C-reactive protein (>5 mg/l)
often accompanied by maternal leukocytosis, fever and/or
histological chorioamnionitis (yes or no), premature rup-
ture of the membranes (yes or no, defined as more than
24 hours duration), small for gestational age (below the
10th percentile; yes or no), number of days with infection/
sepsis (mean, range), and maximal grade of retinopathy of
prematurity (RPM; no RPM, stage 1–5) (Table 2).
Enzyme-linked immunosorbent assay (ELISA)
We used an ELISA (Human VEGF Quantikine ELISA Kit
DVE00, R&D Systems GmbH, Wiesbaden-Nordenstadt,
Germany) to determine the relative VEGF-A (here referred
to as VEGF) levels in the tracheal aspirates. The assay is us-
able for tracheal aspirates in according to the recommen-
dations of the company and the minimal detectable VEGF
concentration is less than 5 pg/ml. The VEGF levels were
expressed in pg VEGF/μg total protein in order to adjust
for differential dilution factors. The DMBT1 levels deter-
mined in two earlier studies were used for the comparison,
where they were expressed as percentage of total protein
content: (μg DMBT1/μg total protein) × 100 [18,19].
Stimulation with TNFα, LPS and PMA
Human lung epithelial A549 cells, which were used in
this study, have the characteristic morphology of type II
lung epithelial cells, show typical lamellar bodies and
form confluent monolayers [21]. The cells were stably
Table 2 Correlation of constant parameters with the
VEGF concentration in tracheal aspirates of 57 infants
Parameter p-value
Gestational age (postmenstrual age in weeks,
mean ± standard deviation)
27.5 ± 4.2 0.9230
Birth weight (g, mean ± standard deviation) 1128 ± 839 0.6718
Bronchopulmonary dysplasia (n) 34 (60%) 0.3076
Asphyxia (n) 7 (12%) 0.4642
Intraventricular hemorrhage (all grades) 16 (28%) 0.2607
Cerebral hemorrhage
(intraventricular, cerebellar, n)
17 (30%) 0.2782
Respiratory distress syndrome (n) 50 (88%) 0.7636
Maximal grade of respiratory
distress syndrome (RDS)
0.4284
No RDS (n) 7 (12%)
Grade 1 (n) 6 (11%)
Grade 2 (n) 18 (32%)
Grade 3 (n) 20 (35%)
Grade 4 (n) 6 (11%)
Survival (n) 49 (86%) 0.8802
Antenatal corticosteroids for lung
development (complete, n)
32 (56%) 0.9443
Maternal infection (n) 23 (40%) 0.4403
Premature rupture of the membranes (n) 8 (14%) 0.2180
Small for gestational age (n) 15 (26%) 0.4428
Number of days with infection
(median, range)
11 (0–80) 0.7470
Retinopathy of prematurity (n) 34 (60%) 0.9268
Maximal grade of Retinopathy of
prematurity (RPM)
0.6947
No RPM 23 (40%)
Stage 1 (n) 4 (7%)
Stage 2 (n) 16 (28%)
Stage 3 (n) 14 (25%)
Stage 4 (n) 0
Stage 5 (n) 0
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largest (8 kb) DMBT1 variant (DMBT1+ cells) under the
control of a constitutive promoter or with an empty expres-
sion vector (DMBT1- cells) as described previously [22].
A549 cells were cultured with DMEM medium with-
out phenol red (PAN-Biotech, Aidenbach, Germany)
containing 10% fetal bovine serum, 1% L-glutamine and
penicillin/streptomycin. Hygromycin B, used for the se-
lection of cells with insertion of the plasmids, was added
at a final concentration of 500 μg/ml to keep the cells
under selection pressure. Cultivation was performed at
37°C and 5% CO2.
In experiments without stimulation 7.5 × 105 cells were
cultured with medium containing fetal bovine serum (FBS)until 90% confluence in a well of a 6-well plate was reached.
The medium was removed and replaced with FBS-free
medium for 48 hours. The supernatants of the confluent
cell culture were then carefully removed, centrifuged at
1,500 rpm to remove remaining cells, and then frozen at
−20°C until determination of the VEGF and IL-6 concentra-
tions. The confluent cells on the cell culture plates were
removed with trypsin from the wells and counted with a
Neubauer chamber. Trypan blue staining was used to count
the viable cells, enabling a calculation of the VEGF and
IL-6 concentration referred to the number of viable cells.
In the case of stimulation the cells were incubated in
FBS-free medium with LPS (10 μg/ml for 48 hours), TNFα
(10 ng/ml for 48 hours) and Phorbol-12-myristate-13-
acetate (PMA; 50 ng/ml for 48 hours). After stimulation
the supernatant was harvested and analyzed for VEGF and
IL-6 as described above.
Determination of VEGF and IL-6 concentrations in
supernatants of A549 cells by ELISA
The expression of VEGF-A and IL-6 in the supernatants
of A549 cells was measured with an ELISA for human
VEGF and for human IL-6 (Human VEGF Quantikine
ELISA Kit DVE00 and Human IL-6 Quantikine ELISA Kit
D6050, R&D Systems GmbH, Wiesbaden-Nordenstadt,
Germany). The assays are both usable for cell culture
supernatants in according to the recommendations of the
company. The minimal detectable VEGF concentration is
less than 5 pg/ml and the minimal detectable IL-6 concen-
tration is less than 0.70 pg/ml. The VEGF and IL-6 concen-
trations were then calculated in pg/ml/100,000 viable cells.
Western blot
Western blot analysis was performed to confirm DMBT1
expression in DMBT+ versus DMBT1- cells by using a poly-
acrylamide gel and non-reducing conditions. The polyclonal
antibody anti-DMBT1p84 was used to detect DMBT1 as
described previously [7]. An antibody against heavy chain
non-muscle myosin (NMMHC, DPC Biermann, Bad
Nauheim, Germany), a structure protein like β-actin,
was employed as reference protein to allow comparison
of the different samples. After incubation with the sec-
ondary antibody anti-rabbit-IgG conjugated to horse-
radish peroxidase the analyzed proteins were detected and
visualized by ECL Western Blotting Substrate.
Statistics
All statistical calculations have been done with SAS soft-
ware, release 9.3 (SAS Institute Inc., Cary, NC, USA). For
categorical parameters, absolute and relative frequencies
are given. Quantitative parameters are presented as mean
value and standard error of mean (SEM) together with
minimum and maximum. In the case of outliers the median
value has been calculated. In order to estimate correlations
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concentrations, gestational age, birth weight) and the out-
come variable “VEGF level”, regression analyses have been
used. Variance analyses have been performed for testing the
influence of qualitative parameters on the outcome variable.
To create a formula calculating the VEGF content of an un-
known tracheal aspirate we performed a multiple regression
analysis. All these analyses have been performed with the
SAS procedure PROC MIXED where patients’ ID was con-
sidered as a random variable and the parameters being
tested as fixed variables. Furthermore, we compared
DMBT1+ versus DMBT1- cells regarding VEGF and IL6-
levels using the 2 sample t-tests or Mann–Whitney U-tests
as appropriate. Test results with p-values smaller than
0.05 were regarded as statistically significant. In cases
of multiple comparisons we performed a correction for
multiple testing.
Results
VEGF concentrations in tracheal aspirates
The mean VEGF-A (hereafter referred to as VEGF)
concentration in the tracheal aspirates of the 57 preterm
and term infants was 0.7524 ± 0.8882 pg/μg total protein
with a range of 0.008 to 4.609 pg/μg total protein. The
relative VEGF levels were significantly associated with
the postnatal age, the earlier determined DMBT1 levels
[18,19] in the tracheal aspirates and with neonatal infec-
tion/sepsis (Table 1, Figure 1). The other parameters, in-
cluding gestational age, birth weight, bronchopulmonary
dysplasia, respiratory distress syndrome and retinopathy
of prematurity, showed no association with the relative
VEGF levels of the tracheal aspirates (Table 2).
Furthermore, we performed a multiple regression ana-
lysis including these factors, which have been revealed as
statistically significant, in the univariate analyses. This
led to the following mathematical equation:
y ¼ 0:2840 þ 0:007356x1 þ 0:1569x2 þ x3
where Y is the relative VEGF level (pg VEGF/μg total
protein) in the unknown tracheal aspirate, which is
significantly influenced by the parameters postnatal age
(in days, X1, p = 0.0427), the relative DMBT1 level
expressed as percentage of the total protein concentra-
tion (μg DMBT1/μg total protein × 100) in the tracheal
aspirate (X2, p = 0.0159) and the presence or absence of
neonatal infection/sepsis (x3 = 0.4891, if the infant has
an infection/sepsis or x3 = 0 in the absence of infection/
sepsis; p = 0.0038).
In conclusion, correlation of VEGF levels with postna-
tal age, infection/sepsis and DMBT1 levels is in good
agreement with the findings that DMBT1 levels also cor-
related with postnatal age and infection/sepsis according
to an earlier study [18].DMBT1 promotes basal and inducible VEGF expression in
A549 cells
Because the VEGF and the DMBT1 levels in the tracheal
aspirates were significantly correlated, we next tested as
to whether this might be based on a causal relationship.
We therefore employed A549 lung epithelial cells with
and without DMBT1 expression. DMBT1-positive A549
cells (referred to as DMBT1+ cells) were constructed
using the expression plasmids described before [22].
Control cells were constructed in parallel using an
empty expression plasmid. Western blot analyses con-
firmed expression in DMBT1+ cells, while no detectable
protein levels were observed for A549 cells carrying the
empty expression plasmid (Figure 2), so that we will
refer to the latter as DMBT1- cells.
We next determined the basal VEGF levels in the two
cell lines as well as the VEGF levels after stimulation
with TNFα, LPS, or PMA. DMBT1+ cells displayed sig-
nificantly elevated VEGF levels in the basal state as well
as after stimulation, regardless of whether TNFα, LPS,
or PMA was used (Figure 3). This clearly indicated that
the presence of DMBT1 primes the lung epithelial cells
for an enhanced VEGF production and confirms a causal
relationship.
DMBT1 suppresses IL-6 production in A549 cells
IL-6 is a well-known pro-inflammatory mediator in re-
spiratory tract tissues, and, among various other effects,
elicits increased VEGF production [23]. On the other
hand, studies of intestinal inflammation in Dmbt1−/−
mice revealed that, in this tissue, DMBT1 may function
in suppression of inflammation and IL-6 production via
a role as pattern recognition molecule [5,6,24]. We thus
evaluated next the IL-6 levels in alveolar epithelial A549
cells with and without DMBT1 expression. In the ab-
sence of inflammatory stimuli, DMBT1 did not elicit
significant changes in IL-6 levels. By contrast, compared
to DMBT1- cells, the DMBT1 expressing A549 cells dis-
played significant suppression of IL-6 production after
stimulation with any of the three pro-inflammatory stimuli
(TNFα, LPS, and PMA; Figure 4). This remarkably sug-
gested that DMBT1 may substitute the IL-6 function in
up-regulation of VEGF.
Discussion
Proper spatio-temporal regulation of VEGF production
is of critical importance for the respiratory tract. A dis-
tinct VEGF gradient is required for development of the
airway tubular structures and lung endothelium, while
VEGF overexpression may lead to dysmorphogenesis of
the lung [9]. In pulmonary diseases like ARDS VEGF
can aggravate the disease in a concentration-dependent
manner by induction of endothelial permeability or can
support the healing process. Different mechanisms are
Figure 2 DMBT1 expression in DMBT1+ and DMBT1- cells.
Western blotting using the polyclonal antibody anti-DMBT1p84
confirmed a high DMBT1 expression in DMBT1+ cells whereas no
DMBT1 expression was observed in DMBT1- cells. Heavy chain
non-muscle myosin (NMMHC), a structure protein like β-actin,
was used as reference protein to examine equal loading of the
samples. Lane 1: DMBT1+ cells, lane 2: DMBT1- cells.
Figure 1 Significant correlations between VEGF levels and
tested parameters. Correlations were established by testing of
tracheal aspirates (n = 120) from infants and tested for significance
via regression analysis or ANOVA using the SAS procedure PROC
MIXED. (A) VEGF levels were significantly correlated with the
postnatal age of the infants (p = 0.0073). (B) Positive correlation of VEGF
levels with relative DMBT1 levels in the tracheal aspirates (p = 0.0032).
(C) Significantly increased VEGF levels (mean ± SEM) in aspirates from
infants with versus without infection/sepsis (p = 0.0002).
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the loss of pneumocytes type II leads to decreased VEGF
production. Secondly, proteases from inflammatory cells
can degrade VEGF. Thirdly, more pulmonary VEGF can
leave the lung across the alveolar-capillary barrier upon
increased permeability. At fourth, soluble VEGFR-1, a
splice variant of the membrane bound VEGFR-1, is apotent antagonist of the bioactive VEGF and influences
the bioactivity of the VEGF present in the lung. Finally,
other inhibitors of VEGF bioactivity in the lung contribute
to its regulation such as ADAMTS1 and connective tissue
growth factor [15,25]. Because understanding VEGF regu-
lation is thus critical for understanding the basis of respira-
tory disease, we here addressed possible links between the
secreted factor DMBT1 and VEGF.
Influence of perinatal factors on VEGF levels in the
tracheal aspirates of preterm and term infants
Our study revealed a correlation between the VEGF
levels and postnatal age, but not with the gestational age
or birth weight. This is in agreement with the study of
Lassus et al., who examined 189 tracheal aspirates of 44
preterm infants in the first postnatal week and described
an increase of VEGF concentration and no correlation
with gestational age or birth weight [26]. However, in
contrast to our study higher VEGF concentrations in
infants of mothers with chorioamnionitis or premature
rupture of the membranes and lower VEGF concentrations
in infants with BPD or maternal preeclampsia were re-
ported. Additionally, a negative correlation between VEGF
levels and the number of surfactant doses was demon-
strated in this study [26]. Another studies reported reduced
VEGF levels in bronchopulmonary dysplasia of preterm in-
fants, which is a neonatal chronic lung disease with reduced
number of alveoles and reduced microvascular density
[17,27]. Moreover, other authors reported that VEGF levels
in tracheal aspirates of mechanically ventilated preterm
neonates are not associated with BPD. Also in this study no
correlation between birth weight and VEGF levels or
Figure 3 VEGF levels in unstimulated and stimulated DMBT1+ and DMBT1- cells. VEGF levels were determined in cell culture supernatants
by ELISA. DMBT1+ cells showed significantly elevated VEGF levels in the basal state without stimulation as well as after stimulation with TNFα,
LPS, or PMA. The VEGF mean values of the cell culture wells are shown for different stimulations and separately for DMBT1+ and DMBT1- cells.
Error bars represent standard error of the mean. Sample sizes of the eight resulting subgroups were between 5 and 14. The p values were derived
from 2 sample t-tests which have been used to compare the VEGF mean values for DMBT1+ and DMBT1- cells.
Figure 4 Analysis of IL-6 levels in DMBT1+ and DMBT1- cells. IL-6 levels were determined by ELISA in cell culture supernatants of DMBT1+
and DMBT1- cells (A) without stimulation, (B-D) after stimulation with the respective agents. In the absence of inflammatory stimuli, DMBT1 had
no significant effect on IL-6 levels. Compared to DMBT1- cells DMBT1+ cells showed significant suppression of IL-6 production after stimulation
with the pro-inflammatory stimuli (TNFα, LPS, and PMA). The means of 5–14 cell culture wells are shown. Error bars represent standard error of
the mean. Statistical significance has been evaluated using Mann–Whitney U-tests because the data lacked normal distribution.
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be detected [28]. In summary, our data confirm an
increase of VEGF levels with postnatal age as reported
by other authors [26].
Correlation between pulmonary DMBT1 and VEGF levels
in tracheal aspirates of preterm and term infants
The VEGF concentrations determined in this study for
the tracheal aspirates of preterm and term infants
showed a significant correlation with the DMBT1 levels
determined earlier [18,19]. Confirmed causal relation
was established by the significantly higher VEGF con-
centrations in the supernatants of the DMBT1+ cells in
comparison to the DMBT1- cells. Thus, DMBT1 not
only may interact with VEGF [7], but obviously is also a
positive regulator of VEGF in type II lung cells.
VEGF regulation in the respiratory tract
Inflammation and angiogenesis are intimately linked to
each other. VEGF may affect immune surveillance and
modulation [9]. IL-6 and TNFα, both involved in in-
creased vascular permeability and remodeling, are able
to induce VEGF expression and IL-6 as well as VEGF
are up-regulated in response to hypoxia [25]. In early
stages of acute lung injury the pro-inflammatory cyto-
kines induce the expression and release of VEGF from
pneumocytes type II, alveolar macrophages and neutro-
phils [25]. The observation that A549 cells constitutively
produced VEGF was confirmed by different studies
[29-31]. Clinical studies showed that LPS-induced lung
injury is characterized by an increased pulmonary VEGF
expression [25]. Prostacyclin-induced VEGF production
is cyclooxygenase-2-dependent and PMA induced the
expression of COX-2 [32,33]. PMA is an activator of the
protein kinase C. The induction of VEGF by PMA via
protein kinase C activation is also known from human
endothelial cells [34]. Luo et al. reported about a non-
significant increase of VEGF after stimulation of A549
cells with PMA (0.1 μM for 12 hours), but the stimula-
tion with both, PMA and COX-2, led to a significant
increase of VEGF expression [35]. In our study, we
observed an increase of VEGF expression, when stimu-
lating A549 cells with 50 ng/ml PMA for 48 hours.
Other studies showed that inhibition of the protein kin-
ase C led to significantly decreased VEGF secretion in
primary human airway epithelial cells [36]. We observed
that DMBT1 significantly elevated VEGF levels in type II
lung cells in the basal state as well as after stimulation
with pro-inflammatory agents. Within the light of the
recently established role of DMBT1 in angiogenesis [7]
it is thus conceivable that DMBT1, besides active partici-
pation in innate immunity, participates in the initiation
of regeneration and/or in the transition from inflamma-
tion to regeneration in the respiratory tract.DMBT1-mediated IL-6 suppression
Pro-inflammatory stimuli induce a stimulation of NF-κB
followed by induced transcription of pro-inflammatory
mediators such as IL-6, COX-2 and TNFα. The pro-
inflammatory cytokines IL-6 and TNFα are secreted to
the tracheal aspirate fluid of infants with meconium as-
piration syndrome [37]. Pulmonary IL-6 is increased in
preterm infants developing BPD and in BPD lungs [38].
Further, the tracheal aspirate cells from preterm infants
developing BPD showed an increased activation of NF-κB
[39]. LPS (1 μg/ml for 24 hours) induced the expression of
IL-1β, IL-6, IL-8 in A549 cells [40]. Under our experimen-
tal conditions, no increase of IL-6 after LPS-treatment
was observed in the DMBT1- A549 cells and a decrease of
IL-6 was found in the DMBT1+ cells. The up-regulation
of IL-6 upon PMA stimulation [41] was confirmed in our
study in the DMBT1- and DMBT1+ cells, but the effect is
much higher in the DMBT1- cells (DMBT1- cells: 160–
fold, DMBT1+ cells: 20-fold). The same is the case after
stimulation with TNFα: The IL-6 increase is 100-fold in
control cells and 10-fold in DMBT1 cells. Thus, we con-
sistently observed that DMBT1 suppressed IL-6 in type II
lung cells, when challenged with pro-inflammatory stim-
uli. This is in good agreement with data showing that
Dmbt1−/− mice were more susceptible to colitis and
showed elevated mRNA levels for IL-6 and TNF during
inflammation [5]. DMBT1 was up-regulated in intestinal
epithelial cells after stimulation with LPS or TNFα, but is
also able to inhibit LPS-induced NF-κB activation and
cytokine secretion [6]. In intestinal epithelial cells DMBT1
is known to interact with LPS and to antagonize the
actions of LPS [42]. Taken together, this may point to anti-
inflammatory functions of DMBT1 in lung epithelial cells
via suppression of IL-6 induction in the presence of pro-
inflammatory stimuli, and that DMBT1 may substitute IL-
6’s functions in up-regulating VEGF. This would be in
good agreement with the assumption that DMBT1 may
have additional functions at the transition from resolution
of inflammation to regeneration in the respiratory tract
and other tissues.Conclusions
Our data indicate that increased DMBT1 expression
induces the production of VEGF and suppresses the IL-6
response in lung epithelial cells, which may point to a func-
tion in the transition from inflammation to regeneration.Abbreviations
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